EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CRAFITY and AFP/PIVKA-II Kinetics Predict Prognosis in Hepatocellular Carcinoma on Immunotherapy

Shou-Wu Lee iD, Yi-Jie Huang iD, Ying-Cheng Lin, Hsin-Ju Tsai iD, Chia-Chang Chen, Chung-Hsin Chang, Teng-Yu Lee iD, Yen-Chun Peng

Cancers · 18.09.2025 · 17 (18) · 3058

DOI: 10.3390/cancers17183058 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 18.09.2025. Verfasst von Shou-Wu Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407219, Taiwan. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The CRAFITY score, integrating baseline C-reactive protein (CRP) and alpha-fetoprotein (AFP), has been validated as a prognostic biomarker in hepatocellular carcinoma (HCC) treated with immunotherapy, but many patients present with non-elevated AFP, limiting its accuracy. This study evaluated a composite model incorporating the CRAFITY score with AFP/PIVKA-II kinetic changes.

Methods

We retrospectively enrolled 69 patients with unresectable HCC (BCLC stage B/C) receiving immunotherapy between September 2021 and June 2023. Baseline CRP, AFP, and PIVKA-II, as well as 4-week changes, were recorded. The CRAFITY-100 RULE combined CRAFITY (0–2) with AFP/PIVKA-II kinetics (0–3), yielding three risk levels (I–III). Clinical outcomes included objective response (OR) and overall survival (OS).

Results

Of the cohort, 10 (14.5%), 29 (42%), and 30 (43.5%) patients had CRAFITY scores 0, 1, and 2, respectively, but this score did not clearly stratify OS (median 24, 12, and 15 months; p = 0.267). In contrast, the CRAFITY-100 RULE classified 5 (7.3%), 35 (50.7%), and 29 (42%) patients into levels I–III, respectively, with significantly different survival (median OS 24, 15, and 7 months; p = 0.048). OR rates were lowest at level III (17%). Time-dependent ROC analysis confirmed superior discrimination of CRAFITY-100 RULE over CRAFITY scores at 6 months (AUROC 0.673 vs. 0.604) and 12 months (0.732 vs. 0.656).

Conclusions

The CRAFITY-100 RULE provided clearer stratification and higher discrimination. This simple model integrating baseline and dynamic biomarkers may assist clinical decision-making in unresectable HCC treated with immunotherapy.

Schlagwörter

Stichwörter der Autor:innen

AFPCRPPIVKA-IIhepatocellular carcinoma

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407219, Taiwan.
  • Department of Internal Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.
  • Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 402, Taiwan.
  • Department of Internal Medicine, National Yang Ming Chiao Tung University, Taipei 30010, Taiwan.

ORCID-Profile: Shou-Wu Lee, Yi-Jie Huang, Hsin-Ju Tsai, Teng-Yu Lee

Zitieren

APA

Lee, S. W., Huang, Y. J., Lin, Y. C., Tsai, H. J., Chen, C. C., Chang, C. H., Lee, T. Y., & Peng, Y. C. (2025). CRAFITY and AFP/PIVKA-II Kinetics Predict Prognosis in Hepatocellular Carcinoma on Immunotherapy. Cancers, 17(18), 3058. https://doi.org/10.3390/cancers17183058

Vancouver

Lee SW, Huang YJ, Lin YC, Tsai HJ, Chen CC, Chang CH, et al. CRAFITY and AFP/PIVKA-II Kinetics Predict Prognosis in Hepatocellular Carcinoma on Immunotherapy. Cancers. 2025;17(18):3058. doi:10.3390/cancers17183058

BibTeX
@article{Lee2025,
  author = {Lee, Shou-Wu and Huang, Yi-Jie and Lin, Ying-Cheng and Tsai, Hsin-Ju and Chen, Chia-Chang and Chang, Chung-Hsin and Lee, Teng-Yu and Peng, Yen-Chun},
  title = {CRAFITY and AFP/PIVKA-II Kinetics Predict Prognosis in Hepatocellular Carcinoma on Immunotherapy},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {18},
  pages = {3058},
  doi = {10.3390/cancers17183058}
}
Kostenlos starten →